Humacyte, Inc. Common Stock
Here’s whether Humacyte, Inc. Common Stock (HUMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+7.78% over 10 days); 3-month momentum positive (+12.5%). Concerns: RSI 70 — overbought, elevated pullback risk; weak 1-year return of -48.5%. Currently 53.9% off its 52-week high. Score: +3/7.
HUMA is in a confirmed uptrend, trading above both its 50-day ($0.89) and 200-day ($1.21) moving averages. With an RSI of 70.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -48.5% compares to +24.4% for SPY (trailed the market by 72.8%). The current 53.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.